Independent prognostic factors for response: updated results of the ABCSG-24 study evaluating the addition of capecitabine to epirubicin-docetaxel neoadjuvant therapy for early breast cancer (EBC) Veröffentlicht vonadmin 27. Juli 2020 Steger, GG, Greil, R, Jakesz, R, Lang, A, Mlineritsch, B, Rudas, M, Marth, C, Stoeger, H, Singer, CF, Gnant, M